Analysts Expect MorphoSys AG Unsponsored ADR (NYSE:MOR) Will Post Earnings of -$0.38 Per Share

Equities research analysts predict that MorphoSys AG Unsponsored ADR (NYSE:MOR) will post ($0.38) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for MorphoSys’ earnings, with the lowest EPS estimate coming in at ($0.42) and the highest estimate coming in at ($0.33). MorphoSys posted earnings per share of ($0.39) in the same quarter last year, which would suggest a positive year-over-year growth rate of 2.6%. The company is expected to report its next earnings report on Wednesday, March 11th.

According to Zacks, analysts expect that MorphoSys will report full year earnings of ($0.88) per share for the current fiscal year, with EPS estimates ranging from ($0.94) to ($0.82). For the next financial year, analysts forecast that the business will report earnings of ($0.64) per share, with EPS estimates ranging from ($1.31) to $0.03. Zacks’ earnings per share calculations are an average based on a survey of analysts that that provide coverage for MorphoSys.

Separately, Svb Leerink reissued an “outperform” rating on shares of MorphoSys in a research note on Tuesday, January 14th.

Shares of MOR traded down $0.72 during trading hours on Friday, reaching $30.76. The company’s stock had a trading volume of 93,438 shares, compared to its average volume of 116,426. MorphoSys has a 1-year low of $22.46 and a 1-year high of $37.96. The company has a 50 day moving average of $33.54 and a two-hundred day moving average of $30.59.

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Read More: How is a buy-side analyst different from a sell-side analyst?

Get a free copy of the Zacks research report on MorphoSys (MOR)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with's FREE daily email newsletter.